Browse NRBF2

Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Cytoplasmic vesicle Cytoplasmic vesicle, autophagosome
Domain PF08961 Nuclear receptor-binding factor 2
PF17169 MIT domain of nuclear receptor-binding factor 2
Function

May modulate transcriptional activation by target nuclear receptors. Can act as transcriptional activator (in vitro). ; FUNCTION: Involved in starvation-induced autophagy probably by its association with PI3K complex I (PI3KC3-C1). However, effects has been described variably. Involved in the induction of starvation-induced autophagy (PubMed:24785657). Stabilzes PI3KC3-C1 assembly and enhances ATG14-linked lipid kinase activity of PIK3C3 (By similarity). Proposed to negatively regulate basal and starvation-induced autophagy and to inhibit PIK3C3 activity by modulating interactions in PI3KC3-C1 (PubMed:25086043). May be involved in autophagosome biogenesis (PubMed:25086043). May play a role in neural progenitor cell survival during differentiation (By similarity).

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006914 autophagy
GO:0010506 regulation of autophagy
GO:0019216 regulation of lipid metabolic process
GO:0034976 response to endoplasmic reticulum stress
GO:0043550 regulation of lipid kinase activity
Molecular Function -
Cellular Component GO:0005776 autophagosome
GO:0005942 phosphatidylinositol 3-kinase complex
GO:0019898 extrinsic component of membrane
GO:0035032 phosphatidylinositol 3-kinase complex, class III
GO:0061695 transferase complex, transferring phosphorus-containing groups
> KEGG and Reactome Pathway
 
KEGG hsa04140 Regulation of autophagy
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NRBF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NRBF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.70; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.41; FDR: 0.02150 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NRBF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2350.284
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.480.793
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0580.965
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.170.524
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2940.826
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.010.996
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0120.973
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1170.934
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1880.907
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4390.677
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7530.655
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.110.115
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NRBF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NRBF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NRBF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NRBF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NRBF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NRBF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NRBF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNRBF2
Namenuclear receptor binding factor 2
Aliases DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NRBF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.